If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
Receive an email update when we add a new PRECISION MEDICINE article.
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Sparrow's Genomic Tumor Board gives patients more treatment options on February 20, 2019 at 4:06 pm
But doctors are learning the key to successful cancer treatment may be hidden inside the patient. Members of Sparrow's Genomic Tumor Board are the first in the country to work closely with a genomic t... […]
- Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine on February 20, 2019 at 2:04 pm
Standard chemotherapy is associated with low responses and considerable toxicity, highlighting clinical need for better therapies," commented Aditya Bardia, MD, MPH, lead author of the article and Dir... […]
- Antibody-drug conjugate shows promise against metastatic triple-negative breast cancer on February 20, 2019 at 2:04 pm
director of Precision Medicine at the MGH Cancer Center's Center for Breast Cancer and assistant professor of Medicine at Harvard Medical School. A randomized, phase 3 clinical trial (ASCENT) of sacit... […]
- Cancer Profiling Market Revenues Surpassed US$ 900 Million in 2018 on February 19, 2019 at 4:30 am
... Significant economic burden associated with cancer diagnosis and treatment Growing R&D investments to develop effective cancer diagnostics Increasing importance of precision medicine adoption and ... […]
- The Challenge of Precision Medicine in mCRPC on February 18, 2019 at 6:20 am
This is personalized care. We have now entered the era of precision medicine. In 1971, President Nixon declared a “war on cancer” by signing the National Cancer Act. Those of us who are old enough to ... […]
- PSBJ Interview: Fred Hutch veteran Dr. Carla Grandori is flipping the script on cancer treatment on February 16, 2019 at 3:00 am
The Italian-born scientist built on the breakthrough by assembling a team of cancer experts from UW, Fred Hutch and Providence St. Joseph Health, founding SEngine Precision Medicine Inc. in 2015. The ... […]
- Next Generation Precision Oncology Symposium Celebrates Survivors, Current and Future on February 15, 2019 at 9:33 am
The Next Generation Precision Oncology Symposium, a novel meeting of industry and academic leaders in cancer science and medicine, will be held February 21, 2019 at UC San Diego Moores Cancer Center. ... […]
- Miami Cancer Institute adopts Philips IntelliSpace Precision Medicine Genomics on February 14, 2019 at 11:00 am
- Miami Cancer Institute, part of Baptist Health South Florida, implements Philips' cloud-based comprehensive genomics platform to inform cancer treatment options through advanced diagnostic testing ( ... […]
- Brahmer Calls for Better Incorporation of Precision Medicine in Lung Cancer on February 14, 2019 at 10:08 am
There may be potential for immunotherapy in lung cancer beyond PD-1/PD-L1 and CTLA-4 inhibitors, said Julie R. Brahmer, MD, but first, researchers need to gain a better understanding of resistance mec... […]
via Bing News